159 related articles for article (PubMed ID: 38672622)
1. BUB1 Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Inhibiting Ferroptosis.
Wang W; Zhou X; Kong L; Pan Z; Chen G
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672622
[TBL] [Abstract][Full Text] [Related]
2. Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches.
Ashrafizadeh M; Luo K; Zhang W; Reza Aref A; Zhang X
Environ Res; 2024 Jan; 240(Pt 2):117443. PubMed ID: 37863168
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs.
Qi R; Bai Y; Li K; Liu N; Xu Y; Dal E; Wang Y; Lin R; Wang H; Liu Z; Li X; Wang X; Shi B
Drug Resist Updat; 2023 May; 68():100960. PubMed ID: 37003125
[TBL] [Abstract][Full Text] [Related]
4. Synergistic ferroptosis-gemcitabine chemotherapy of the gemcitabine loaded carbonaceous nanozymes to enhance the treatment and magnetic resonance imaging monitoring of pancreatic cancer.
Zhang G; Li N; Qi Y; Zhao Q; Zhan J; Yu D
Acta Biomater; 2022 Apr; 142():284-297. PubMed ID: 35151925
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition.
Jin H; Zhao Y; Zhang S; Yang J; Zhang X; Ma S
Mol Med Rep; 2018 May; 17(5):7274-7280. PubMed ID: 29568909
[TBL] [Abstract][Full Text] [Related]
6. CircHIPK3 Promotes Gemcitabine (GEM) Resistance in Pancreatic Cancer Cells by Sponging miR-330-5p and Targets RASSF1.
Liu Y; Xia L; Dong L; Wang J; Xiao Q; Yu X; Zhu H
Cancer Manag Res; 2020; 12():921-929. PubMed ID: 32104074
[TBL] [Abstract][Full Text] [Related]
7. S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway.
Liu Y; Bi T; Liu L; Gao Q; Shen G; Qin L
Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):615-622. PubMed ID: 30683944
[TBL] [Abstract][Full Text] [Related]
8. Cancer-associated fibroblasts promote stemness maintenance and gemcitabine resistance via HIF-1α/miR-21 axis under hypoxic conditions in pancreatic cancer.
Deng K; Zou F; Xu J; Xu D; Luo Z
Mol Carcinog; 2024 Mar; 63(3):524-537. PubMed ID: 38197482
[TBL] [Abstract][Full Text] [Related]
9. Long Noncoding RNA HCP5 Regulates Pancreatic Cancer Gemcitabine (GEM) Resistance By Sponging Hsa-miR-214-3p To Target HDGF.
Liu Y; Wang J; Dong L; Xia L; Zhu H; Li Z; Yu X
Onco Targets Ther; 2019; 12():8207-8216. PubMed ID: 31632071
[TBL] [Abstract][Full Text] [Related]
10. Chrysin induces autophagy-dependent ferroptosis to increase chemosensitivity to gemcitabine by targeting CBR1 in pancreatic cancer cells.
Zhou L; Yang C; Zhong W; Wang Q; Zhang D; Zhang J; Xie S; Xu M
Biochem Pharmacol; 2021 Nov; 193():114813. PubMed ID: 34673014
[TBL] [Abstract][Full Text] [Related]
11. KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma.
He H; Liang L; Huang J; Jiang S; Liu Y; Sun X; Li Y; Cong L; Jiang Y
Front Pharmacol; 2022; 13():1007429. PubMed ID: 36225575
[TBL] [Abstract][Full Text] [Related]
12. CASP1 is a target for combination therapy in pancreatic cancer.
Wang X; Chen Z; Nie D; Zeng X; Zhong M; Liu X; Zhong S; Wang L; Liao Z; Chen C; Li Y; Zeng C
Eur J Pharmacol; 2023 Dec; 961():176175. PubMed ID: 37949157
[TBL] [Abstract][Full Text] [Related]
13. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
[TBL] [Abstract][Full Text] [Related]
14. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
[TBL] [Abstract][Full Text] [Related]
15. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation.
Ricciardiello F; Gang Y; Palorini R; Li Q; Giampà M; Zhao F; You L; La Ferla B; De Vitto H; Guan W; Gu J; Zhang T; Zhao Y; Chiaradonna F
Oncogene; 2020 May; 39(20):4103-4117. PubMed ID: 32235891
[TBL] [Abstract][Full Text] [Related]
16. Vitamin C Sensitizes Pancreatic Cancer Cells to Erastin-Induced Ferroptosis by Activating the AMPK/Nrf2/HMOX1 Pathway.
Liu Y; Huang P; Li Z; Xu C; Wang H; Jia B; Gong A; Xu M
Oxid Med Cell Longev; 2022; 2022():5361241. PubMed ID: 35915609
[TBL] [Abstract][Full Text] [Related]
17. Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine.
Dai S; Peng Y; Zhu Y; Xu D; Zhu F; Xu W; Chen Q; Zhu X; Liu T; Hou C; Wu J; Miao Y
Biomed Pharmacother; 2020 Jan; 121():109521. PubMed ID: 31689601
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation.
Lin Q; Qian Z; Jusko WJ; Mager DE; Ma WW; Straubinger RM
J Pharmacol Exp Ther; 2021 Jun; 377(3):370-384. PubMed ID: 33753538
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
Liu S; Ge Y; Wang T; Edwards H; Ren Q; Jiang Y; Quan C; Wang G
Oncol Rep; 2017 Jun; 37(6):3377-3386. PubMed ID: 28440428
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory Effect of Oat Bran Ethanol Extract on Survival and Gemcitabine Resistance of Pancreatic Cancer Cells.
Kim M; Mun JG; Lee HJ; Son SR; Lee MJ; Kee JY
Molecules; 2019 Oct; 24(21):. PubMed ID: 31652886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
